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Background: Complex local and systemic immune dysfunction in glioblastoma (GBM)
may affect survival. Interleukin (IL)-6 and YKL-40 are pleiotropic biomarkers present in
the tumor microenvironment and involved in immune regulation. We therefore analyzed
plasma IL-6, YKL-40, and genetic variation in YKL-40 and explored their ability to
distinguish between glioma subtypes and predict survival in GBM.
Methods: One hundred fifty-eight patients with glioma WHO grade II-IV were included
in the study. Plasma collected at surgery was analyzed for IL-6 and YKL-40 (CHI3L1) by
ELISA. CHI3L1 rs4950928 genotyping was analyzed on whole-blood DNA.
Results: Neither plasma IL-6 nor YKL-40 corrected for age or rs4950928 genotype
could differentiate GBM from lower grade gliomas. GC and GG rs4950928 genotype
were associated with lower plasma YKL-40 levels (CC vs. GC, p = 0.0019; CC vs.
GG, p = 0.01). Only 10 and 14 out of 94 patients with newly diagnosed GBM had
elevated IL-6 or YKL-40, respectively. Most patients received corticosteroid treatment
at time of blood-sampling. Higher pretreatment plasma IL-6 was associated with short
overall survival (OS) [HR = 1.19 (per 2-fold change), p = 0.042] in univariate analysis.
The effect disappeared in multivariate analysis. rs4950928 genotype did not associate
with OS [HR = 1.30, p = 0.30]. In recurrent GBM, higher YKL-40 [HR = 2.12 (per 2-
fold change), p = 0.0005] but not IL-6 [HR = 0.99 (per 2-fold change), p = 0.92] were
associated with short OS in univariate analysis.
Conclusion: In recurrent GBM high plasma YKL-40 may hold promise as a prognostic
marker. In newly diagnosed GBM perioperative plasma IL-6, YKL-40, and genetic
variation in YKL-40 did not associate with survival. Corticosteroid use may complicate
interpretation of results.
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INTRODUCTION
In 1863 Rudolf Virchow described a connection between
inflammation and cancer (1) and thereby laid the foundation
for the present use of immunotherapy as standard of care in
several types of cancer. Regrettably, this is not the case for
glioblastoma (GBM) yet (2, 3). Despite decades of research,
effect of immunotherapy in GBM has been limited (2) and
survival remains poor even with intense trimodal standard
treatment (4). GBM/CNS (Central nervous system) challenges to
immunotherapy include inter- and intratumoral heterogeneity,
low tumor mutational burden, local and systemic immune
evasion, and restricted drug/immune access to the CNS (2, 3, 5).
The complex brain tumor microenvironment promotes
tumor growth, migration, invasion, angiogenesis, and
immunosuppression (6–8). Interleukin (IL)-6, a pleiotrophic
cytokine, and the chitinase-like glycoprotein YKL-40 are
found in glioblastoma tumor cells and cells in the brain
tumor microenvironment (7–12), influence tumor propagating
mechanisms mentioned above (11–17) and inhibition of YKL-40
or IL-6 decrease tumor growth in xenografted glioma mouse
models (15, 17).
IL-6 and YKL-40 regulate each other’s transcription levels
along with a range of other mediators (9, 18) and IL-6 infusion
increased YKL-40 secretion in plasma in healthy volunteers (19).
High or increasing levels of circulating IL-6 or YKL-40 have been
associated with decreased survival of patients with glioma either
alone or in combination with other biomarkers (12, 20–24),
although not consistently (25–30) (Supplementary File 1).
The functional CHI3L1 rs4950928 (-131 C/G) single
nucleotide polymorphism (SNP) correlates with plasma YKL-40
levels in a variety of diseases and healthy subjects (31, 32).
Exploring rs4950928 SNP as an independent biomarker has
revealed ambiguous results (31–34).
The use of circulating biomarkers to assess diagnosis,
response to therapy, tumor recurrences, and prognosis for
brain tumors has many advantages, including the possibility of
repeated measurements and lesser need for invasive surgical
procedures. Immune-related plasma biomarker levels reflect
systemic immune status, which in GBM may mirror complex
neuro-immune interactions and could aid patient- and target-
selection for future trials.
Considering the interaction between IL-6 and YKL-40, their
potential as prognostic biomarkers and treatment targets in
GBM, we explored the prespecified hypotheses that high plasma
IL-6 and YKL-40 pre-treatment or at relapse correlate with
malignancy grade (WHO grade) of gliomas and have an adverse
impact on survival in patients with glioma WHO grade IV.
We further investigated whether the CHI3L1 rs4950928 SNP is
related to increased survival through low plasma YKL-40.
MATERIALS AND METHODS
Patients and Patient Samples
The Copenhagen Brain Tumor Consortium (CBTC) Glio
Research Biobank prospectively includes blood- and tumor
samples obtained during surgery from unselected patients
with gliomas resected at the Neurosurgical Department,
Rigshospitalet, Copenhagen University Hospital, Denmark.
All patients included in the Glio Biobank from 2013 until
January 2017 with available plasma samples (n = 170) were
assessed retrospectively for eligibility. Of these, we included
158 biomarker evaluable patients with histologically confirmed
WHO grade II-IV gliomas (Figure 1). Sample size was limited
by availability of plasma samples. The study cohort includes
samples from initial and/or relapse brain tumor surgery
(Figure 1). Venous blood samples were collected in EDTA vials
(VACUETTE R© K2E K2EDTA) at an unspecified time during the
surgical procedure and stored at 4◦C/on ice for a maximum of
2 h. Plasma was sampled after centrifugation at 3,000 rpm for
10min at 4◦C. Whole-blood and plasma were stored at −80◦C
until analysis.
The main study cohort (Cohort 1) was further divided into
two study populations: Cohort 2 including 94 patients with
GBM and blood samples from their initial surgery and Cohort 3
including 40 patients with GBM and blood samples from relapse
surgery. Of the 94 patients in Cohort 2, 11 patients with GBMhad
paired blood samples from initial and relapse surgery (Cohort
4) (Figure 1).
The study was carried out in accordance with the
recommendations of the Danish Regional Committee on
Health Research Ethics. The protocol was approved by Danish
Regional Committee on Health Research Ethics (Region
Hovedstaden, H-3-2009-136). All subjects gave written informed
consent in accordance with the Declaration of Helsinki.
Covariates, Clinical Follow-Up, and End
Points
Tumor and patient characteristics were found through
retrospective review of medical charts, pathology reports,
and MRI (magnetic resonance imaging) descriptions. Patients
were followed until death or end of follow-up (14th ofMay 2018).
WHO diagnosis, MGMT (O[6]-methylguanine-DNA
methyltransferase) promotor methylation status, 1p-19q
chromosomal deletions, ATRX (α thalassemia/mental
retardation syndrome X-linked) and IDH (isocitrate
dehydrogenase) mutational status were retrieved from
pathology reports. Detection methods differed depending
on time of analysis. IDH mutations were mostly evaluated
by immunohistochemistry (IHC) or by Multiplex Ligation-
dependent Probe Amplification (MLPA). MGMT promoter
methylation was from 2014 primarily analyzed by
pyrosequencing using the Therascreen MGMT Pyro kit (Qiagen)
considering a mean methylation above 10% as positive. Until
then it was determined indirectly by IHC. Date of progression
was found retrospectively through patient charts and MRI
descriptions and based on clinician’s assessment.
YKL-40 and IL-6 Plasma Analysis
Plasma concentration of IL-6 and YKL-40 were determined
retrospectively at Departments of Medicine and Oncology,
Herlev and Gentofte University Hospital, Copenhagen
University Hospital, Denmark. Plasma IL-6 levels were
determined using an enzyme-linked immunosorbent assay
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FIGURE 1 | Study populations and patient selection. CBTC, Copenhagen Brain Tumor Consortium.
(ELISA) (Quantikine high sensitive IL-6, R&D Systems,
Abingdon, Oxon, UK) with a detection limit of 0.01 pg/ml,
an intra-assay CV of <10.5%, and inter-assay CV <17.7%,
with lowest inter-assay CV (<9%) at high IL-6 concentrations
(35). Plasma YKL-40 levels were determined using an ELISA
(Quidel, San Diego, California, USA) with a detection limit of
10 ng/ml, an intra-assay coefficient of variation (CV) of <5%,
and inter-assay CV <6% (36). For both assays, analyses were
performed in accordance with the manufacturers’ instructions.
The biomedical laboratory scientists were blinded to clinical
data. Reference intervals for plasma YKL-40 and IL-6 in healthy
subjects have been defined in previous studies with a median
plasma YKL-40 concentration of 40 ng/mL (36) and median
plasma IL-6 of 1.3 pg/ml, with no significant difference between
serum and plasma values (35).
rs4950928 Genotyping
We retrospectively isolated DNA from whole blood following
standard protocol (937255, Qiasymphony, Qiagen). CHI3L1
rs4950928 genotyping was conducted with Taq-man (Applied
Biosystems by Life Technologies Corporation, Carlsbad, CA,
USA) assays containing a forward (AGTTCCCATAAAAG
GGCTGGTTT) and reverse (CCCAGGCCCTGTACTTCCT
TTATAT) primer for the PCR amplification and a common
(CTCCCCCACGCGGC) and variant (ACTCCCCGACGCGGC)
probe to determine genotype.
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Endpoints and Statistical Analysis
Progression-free-survival (PFS) was calculated for Cohort 2
(newly diagnosed GBM) and defined as time from initial GBM
diagnosis (same date as blood-sampling) until first relapse with
radiological or clinical progression or death without prior history
of relapse. Overall survival (OS) was calculated as time from
blood-sampling until date of death of any cause or end of follow-
up. Two patients in Cohort 2 were lost to follow-up after first
recurrence and were censored for OS analysis.
Plasma concentrations of YKL-40 were converted to age-
corrected percentiles using the established normal YKL-40 level
in healthy individuals (36) or kept as ng/ml values. All YKL-
40 levels referred to are ng/ml unless explicitly called “age-
corrected”. Comparisons were made between normal (≤95th
percentile) and elevated (>95th percentile) (35, 36) IL-6 or age-
corrected plasma YKL-40 levels or log2 transformed (to ensure
linearity) plasma IL-6 and YKL-40. Covariates considered for
multivariate analysis are listed in Supplementary File 2.
Association between plasma IL-6 and YKL-40 levels were
described using the rank correlation. Fisher’s exact test
estimated relation between the CHI3L1 rs4950928 genotype
and WHO tumor grade. A general linear model was used
to evaluate association between plasma biomarker levels and
categorical variables.
Associations between plasma IL-6 and YKL-40 levels and
PFS or OS, respectively, were tested using the Cox proportional
hazards model estimating univariate and multivariate-adjusted
hazard ratios (HR) and 95% confidence intervals (CI). P <
5% were considered significant. Multivariate analysis was only
made for continuous log2 transformed values, since few patients
had elevated IL-6 and/or YKL-40 based on pre-specified cut-
points. The proportional hazards assumption and linearity were
evaluated with martingale residuals. Kaplan-Meier methodology
and the log rank test were used for time-to-event endpoints with
dichotomized covariates.
Calculations were performed using SPSS (v22.0, IBM Corp.,
Armonk, NY) or SAS (v9.4, Cary, N.C.USA).
RESULTS
Patient Characteristics
Ninety-four (Cohort 2) of 134 patients with GBM were newly
diagnosed and 40 patients (Cohort 3) had recurrent GBM at time
of blood-sampling (Figure 1). Twenty-four patients presented
with WHO grade II-III glioma, nine of these were included in
the biobank at relapse surgery. Four out of the 24 WHO grade
II-III gliomas were IDH wildtype, three of these later progressed
to GBM, whereas the fourth was not resected at relapse. All
7 Oligodendroglioma WHO grade II-III tumors had 1p-19q
codeletion analyzed in present or previous tumor samples.
Patient characteristics are listed in Supplementary File 3. At end
of follow-up 116 patients were dead and 40 patients were alive
(2 were lost to follow-up) with a median follow-up time of 134
weeks (Kaplan-Meier method). Median OS in Cohort 2 (newly
diagnosed GBM) was 58 weeks (Supplementary File 3).
Plasma IL-6 and YKL-40 Levels and WHO
Grade, GBM Recurrence and Fluctuation
Over Time
Plasma IL-6 and YKL-40 levels were elevated in GBM compared
to astrocytoma WHO grade II-III (AII-III) patients (p = 0.036;
p = 0.0003). Only plasma YKL-40 levels were higher in patients
with GBM (p = 0.008) compared to oligodendrogliomas WHO
grade II-III (OII-III). When age was added to the model, neither
plasma IL-6 or YKL-40 could differentiate GBM from gliomas
of lower grade at a given age (IL-6, GBM vs. OII-III p = 0.81,
IL-6, GBM vs. AII-III p = 0.88; YKL-40, GBM vs. OII-III p =
0.058; YKL-40, GBM vs. AII-III p = 0.29). Exploring the TCGA
dataset [http://gliovis.bioinfo.cnio.es/ (37)] IL6 andCHI3L1RNA
expression in glioma WHO grade II-IV tumor tissue were both
separately able to differentiate IDH wildtype from IDH mutated
gliomas (p < 0.001; pair-wise t-tests with Bonferroni correction),
with highest expression in IDH wildtype, which should mainly
represent GBMs (Supplementary File 4).
Plasma IL-6 and YKL-40 levels did not differ between the
cohort of newly diagnosed and recurrent GBM (IL-6, p =
0.49; YKL-40, p = 0.066;) (Cohort 2 and 3). Paired plasma
samples from 11 patients with GBM (Cohort 4) displayed multi-
directional variation in IL-6 and YKL-40 levels between time
of diagnosis and relapse (Supplementary File 4). Eight of 11
patients had received standard chemo-radiation therapy [Stupp’s
regimen (38)] between first and second blood-sampling and none
of the eleven patients had MGMT promotor methylation.
Association Between the CHI3L1
rs4950928 Genotype, WHO Tumor Grade,
YKL-40 Plasma Level, and Survival
For 7 patients, whole-blood was not available for genotype
analysis (Figure 1, Supplementary File 3). rs4950928 SNP
genotype distribution did not differ between tumor grades [p =
0.29 (Fisher’s exact test)] but the rs4950928 SNP was significantly
associated with lower YKL-40 plasma levels (CC vs. GC, p =
0.0019; CC vs. GG, p = 0.01) (Figure 2) in Cohort 1. Only 3
FIGURE 2 | Mean plasma YKL-40 by CHI3L1 rs4950928 genotype and
change in percent. P-values are calculated using a general linear model.
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patients were homozygote for the GG genotype. Comparing GC
with CC genotype there were no significant difference in neither
PFS [HR 1.21 (95% CI: 0.76–1.94), p = 0.42] or OS [HR 1.30
(95% CI: 0.79–2.12), p = 0.3] in newly diagnosed GBM (Cohort
2) in univariate analysis and no impact on OS in recurrent GBM
(Kaplan-Meier, p= 0.26).
Associations Between Plasma IL-6 and
YKL-40 and Overall Survival in Patients
With Newly Diagnosed Glioblastoma
In univariate analysis based on log2 transformed plasma
biomarker values higher (per 2-fold change) IL-6 concentrations
were associated with short OS (HR = 1.19, p = 0.042) but
FIGURE 3 | Kaplan-Meier survival curves for (A,B) progression-free survival and (C,D) overall survival in newly diagnosed glioblastoma according to pretreatment
plasma IL-6 and YKL-40. Cut-off: 95th percentile for normal healthy historical controls (4.5 ng/l for IL-6; age-corrected for YKL-40). Dotted lines, >95% percentile;
Black lines, ≤95% percentile. P-values are calculated using log-rank test. OS, overall survival; PFS, Progression-free survival.
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not with PFS (HR = 1.14, p = 0.084). High plasma YKL-40
was associated with short PFS (HR = 1.27, p = 0.011) but
not with short OS (HR = 1.19, p = 0.070). When divided
in high and low plasma IL-6 (cut-off 95% CI in healthy
adults; i.e., ≤4.5 ng/l vs. >4.5 ng/l) and YKL-40 (i.e., age-
corrected 95% CI for healthy adults), only 10 (10.6%) out of 94
patients had elevated IL-6 and 14 (14.9%) had elevated YKL-
40. High age-corrected YKL-40 was associated with short PFS
(log-rank p = 0.007). Other dichotomizations of biomarker
plasma levels did not reveal any association with survival
(Figure 3). Analyzing plasma IL-6 and YKL-40 levels against
covariate categories in newly diagnosed GBM, GG genotype,
and absence of multifocal disease were associated with lower
YKL-40 levels, absence of comorbidity was associated with
lower IL-6, and increasing age was associated with higher
IL-6 and YKL-40 (Table 1). In multivariate analysis neither
continuous plasma IL-6 or YKL-40 levels were associated with
OS or PFS, whereas gender, treatment and MGMT methylation
were independent prognosticators of OS (Table 2) (Reduced
model in Supplementary File 5). Multivariate analysis was only
made for continuous log2 transformed plasma biomarker values
considering the small size of groups resulting from the pre-
specified dichotomization.
Recurrent Glioblastoma
None of the patients with recurrent GBM had IL-6 above 4.5
ng/l and only 5 patients had elevated age-corrected YKL-40. In
TABLE 1 | Pretreatment plasma IL-6 and YKL-40 and patient characteristics for
newly diagnosed glioblastoma.
Plasma biomarkers
and patient
characteristics
Plasma IL-6 Plasma YKL-40
Ratioa 95% CI p-valueb Ratioa 95% CI p-valueb
rs4950928 Genotype
GC vs. CC
1.19 0.80–1.78 0.38 0.76 0.54–1.09 0.13
rs4950928 Genotype
GG vs. CC
2.31 0.65–8.20 0.19 0.27 0.09–0.81 0.021
MGMT
Met vs. Non-met
1.15 0.77–1.71 0.49 0.75 0.53–1.06 0.099
Age (years)
Per 10 years
1.22 1.02–1.45 0.030 1.29 1.11–1.50 0.0011
Gender
F vs. M
1.28 0.86–1.89 0.22 0.82 0.58–1.16 0.27
Treatment
None/RT/TMZ vs.
Stuppc
1.43 0.94–2.17 0.095 1.43 0.98–2.07 0.061
Modified CCId
0 vs. ≥1
0.63 0.41–0.96 0.031 0.70 0.48–1.02 0.066
Multifocal disease
No vs. Yes
1.25 0.58–2.66 0.56 0.48 0.24–0.92 0.028
Degree of resection
Gross-total vs. Partiale
1.09 0.72–1.64 0.68 1.00 0.70–1.43 0.99
aRatio of plasma biomarker level between categories for each variable; bA general linear
model was used to evaluate association between plasma biomarker levels and categorical
variables; cTreatment regimens were dichotomized into no treatment, radiotherapy only
and temozolomide only vs. Stupp’s regimen (radiotherapy, concomitant and adjuvant
temozolomide) and radiotherapy with concomitant temozolomide; d Items solid tumor,
dementia, and hemiplegia were excluded from the Charlson-Comorbidity index if
associated with the brain tumor; eResection status was defined per surgeon’s evaluation.
univariate analysis, higher YKL-40 was associated with short OS
(HR = 2.12, CI 95%: 1.39–3.23, p = 0.0005), whereas IL-6 was
not associated with OS (HR= 0.99, CI 95%: 0.74–1.31, p= 0.92).
DISCUSSION
Although the CNS was previously considered an immune-
privileged site, it is now evident that neuroimmune interactions
within the brain and between brain and circulating immune cells
and molecules are important both in disease and normal brain
function (39). IL-6 and YKL-40 are both involved in complex
immune modulatory systems, cancer propagation, and regulate
each other’s expression (5, 9, 18, 40, 41). In the present study
we evaluated the correlation between IL-6 plasma levels, YKL-
40 plasma levels, CHI3L1 rs4950928 SNP genotype, and survival
of newly diagnosed and recurrent GBM. We also explored
the association between IL-6 and YKL-40 with WHO tumor
grade in gliomas WHO grade II-IV, the association between
CHI3L1 rs4950928 SNP genotype and plasma YKL-40 levels and
differences in plasma IL-6 and YKL-40 levels between patients
with newly diagnosed and recurrent GBM.
TABLE 2 | Pretreatment plasma IL-6 and YKL-40 and prognosis in newly
diagnosed glioblastoma—Multivariate analysis, Full model.
Multivariate analysis
Full Model
n = 74
PFS OS
HR 95% CI p-valuea HR 95% CI p-valuea
IL-6 Log2
Per 2-fold change
0.97 0.79–1.20 0.80 1.06 0.84–1.33 0.62
YKL-40 Log2
Per 2-fold change
1.13 0.89–1.44 0.32 0.99 0.76–1.29 0.96
rs4950928 Genotype
GC vs. CC
1.33 0.73–2.43 0.35 1.37 0.72–2.64 0.34
rs4950928 Genotype
GG vs. CC
1.71 0.17–16.68 0.65 3.36 0.31–35.97 0.32
MGMT
Met vs. Non-met
0.62 0.35–1.09 0.10 0.45 0.24–0.84 0.013
Age (years)
Per 10 years
1.02 0.71–1.46 0.91 1.21 0.80–1.84 0.38
Gender
F vs. M
1.33 0.73–2.41 0.35 2.08 1.08–4.00 0.028
Treatment
None/RT/TMZ vs.
Stuppb
5.19 2.19–12.32 0.0002 2.98 1.27–7.00 0.012
Modified CCIc
0 vs. ≥1
0.73 0.40–1.35 0.31 0.97 0.50–1.88 0.92
Multifocal disease
No vs. Yes
0.52 0.16–1.72 0.29 0.58 0.17–1.96 0.38
Degree of resection
Gross-total vs. Partiald
0.73 0.41–1.30 0.29 0.75 0.40–1.42 0.38
aCox regression analysis; bTreatment regimens were dichotomized into no treatment,
radiotherapy only and temozolomide only vs. Stupp’s regimen (radiotherapy, concomitant
and adjuvant temozolomide) and radiotherapy with concomitant temozolomide; c Items
solid tumor, dementia and hemiplegia were excluded from the Charlson-Comorbidity
index if associated with the brain tumor; dResection status was defined per
surgeon’s evaluation.
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Both plasma IL-6 and YKL-40 levels were higher in
GBM compared to astrocytoma WHO grade II-III, but this
effect disappeared when corrected for age. Each of the two
biomarkers have previously been found to increase in serum
with tumor grade (12, 42), but these studies did not account
for age differences between patients with GBM and lower
grade gliomas.
rs4950928 SNP genotype distribution did not differ between
GBMWHO grades. There was an association between rs4950928
SNP genotype and plasma YKL-40 levels in the entire cohort
but not with PFS or OS in newly diagnosed GBM or OS in
recurrent GBM. This is similar to the results from Boisselier
and colleagues, finding a trend toward higher CHI3L1 RNA
expression in GBM tumor tissue in patients with C allele vs. G
allele, but no association of the rs4950928 SNP with OS (33). The
effect on plasma YKL-40 levels may be a result of methylation on
CHI3L1 CpG sites (43) and changed binding affinity to specific
transcription factors (32). Considering the low prevalence of the
GG genotype [present study (31, 33)], a larger study is necessary
to reject the hypothesis that the GG genotype is linked to survival
benefit in GBM.
In patients with newly diagnosed GBM a high plasma
IL-6 was associated with short OS in univariate analysis. This
effect disappeared in multivariate analysis. IL-6 was associated
with age, comorbidity and non-significantly with treatment
regimen. Diverging results may therefore reflect selection or
confounding bias. Previous studies investigating effect of either
plasma or serum IL-6 levels on glioma survival mostly involve
small cohorts and use a range of cut-offs, sampling times, and
methods of detection (Supplementary File 1). Despite these
limitations, eight out of 10 studies (12, 23–29, 44–46) with
reported survival outcome do not find association of high
plasma IL-6 with short survival (Supplementary File 1),
supporting our results. A study on cytokine networks
including IL-6 in GBM, found a trend toward survival
benefit using a combined IL-4/IL-5/IL-6 serum profile, but
no benefit with a partial combination (24), suggesting that
combined immune-profiles may be related to GBM propagation
and survival.
Investigating YKL-40, we only found high plasma YKL-40
to be associated with short OS in recurrent GBM (univariate
analysis). Multivariate analysis on larger sample sizes are
necessary to confirm this finding. Postsurgical sample collection
(1 week to 48 days after surgery) or measuring changes in
plasma or serum YKL-40 predominated studies finding an
association between high YKL-40 and short survival (21, 22,
26). YKL-40 increases transiently after glioma surgery (20),
whereas IL-6 has been shown to decrease (12), making it
very important to standardize time of blood-sampling to gain
consistent results. Changes in plasma IL-6 and YKL-40 in glioma
could be attributed from tumor mediated regulation of systemic
immune responses, as previously suggested for IL-6 (10, 47,
48) and leakage through a damaged blood-brain barrier, but
inflammatory diseases (32), steroid treatment (49), neutrophilia
(50), and surgical trauma (51, 52) may also influence biomarker
plasma levels.
In our study only few patients had elevated IL-6 and YKL-40
compared to historical healthy controls indicating that systemic
IL-6 and YKL-40 levels may not be key mediators in glioma-
associated systemic immune modulation at time of surgery or
that individual changes are more important than the absolute
plasma concentration. Considering that corticosteroid treatment
may decrease plasma IL-6 (53) and YKL-40 (49) levels and that
only 2 out of 82 patients (Supplementary File 3) in our cohort of
newly diagnosed GBMdid not receive corticosteroid treatment at
blood-sampling, this may also at least partly explain the general
lack of increase in measured plasma biomarkers. Nevertheless,
none of the 5 patients, who received <30mg steroid daily had
increased plasma IL-6 or YKL-40 according to prespecified cut-
points and duration of corticosteroid treatment was unknown.
Limitations in the current study include retrospective data
collection, incomplete information regarding steroid use, lack
of longitudinal measurements, and the unspecified time of
blood collection during surgery. A standard glioma surgery
has a mean duration of 1.5 h at our institution. Therefore,
collecting samples during surgery may have some effect
on IL-6, but only little effect on plasma YKL-40 levels
based on previous IL-6 and TNF-alfa stimulation in healthy
individuals (19).
In conclusion, plasma YKL-40 at time of surgery may
predict survival in recurrent GBM. Plasma IL-6, YKL-40, and
genetic variation in YKL-40 are not associated with survival
at initial GBM surgery but may be difficult to interpret in
patients treated with corticosteroids. Exploring the potential of
more comprehensive combined immune profiles as a minimally
invasive simple method of portraying local and systemic immune
dysregulation is highly relevant.
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